ArticleCureus2025
Intravenous Thrombolysis Administration Rate in Patients With Ischemic Stroke at a Tertiary Private Hospital in Mexico City.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIschemic stroke is a major cause of morbidity and mortality in Mexico; however, national intravenous thrombolysis rates remain low compared to international standards.
objectiveTo evaluate the rate of intravenous thrombolysis in ischemic stroke patients at a private tertiary hospital in Mexico City and to identify clinical and organizational factors associated with treatment delivery.
methodsWe conducted an observational, retrospective, single-center study including 182 ischemic stroke patients admitted between 2021 and 2023. Demographic, clinical, and imaging data were extracted from medical records. Stroke severity was assessed using the NIHSS. Reperfusion therapies, treatment times (door-to-computed tomography [CT], door-to-needle, and door-to-groin), and reasons for exclusion from thrombolysis were documented. Bivariate and multivariate analyses were performed to identify predictors of thrombolysis.
resultsThe mean age was 69.5 years, and 52% (n=95) were men. Hypertension (49.5%, n=90), diabetes (21.4%, n=39), and dyslipidemia (14.3%, n=26) were the most frequent comorbidities. Overall, 39 patients (21.4%) received intravenous thrombolysis, including 13 who also underwent mechanical thrombectomy. Among patients who arrived within 4.5 hours of symptom onset (n=85), 46% (n=39) received thrombolysis; of these, 33 (39% of early arrivers) were treated strictly within the conventional 4.5-hour window. Stroke severity (NIHSS ≥5), anterior circulation involvement, early arrival (<1 hour), concomitant thrombectomy, and shorter door-to-groin times were significantly associated with higher thrombolysis rates. Age, sex, and comorbidities showed no significant association. Only 18% (n=33) of patients achieved a door-to-CT time <25 minutes, 21% (n=38) a door-to-needle time <60 minutes, and 11% (n=20) a door-to-groin time <120 minutes. Hemorrhagic transformation occurred in 20% (n=36), and in-hospital mortality was 9% (n=16), aligning with international registry data.
conclusionsThe thrombolysis rate observed at this tertiary private hospital was higher than national averages, likely due to early recognition of symptoms, access to extended window protocols, and availability of specialized stroke care. Nonetheless, treatment delays remain a significant challenge. Strengthening institutional stroke pathways and reducing door-to-treatment times are key priorities. Broader implementation of streamlined protocols and prehospital notification systems could improve stroke care delivery in middle-income countries like Mexico.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.